Viewing nowZejula Capsules 100 mg (Niraparib Tosylate Monohydrate)
Niraparib Tosylate Monohydrate 159.4mg
Hard capsule · Prescription medication
Takeda Korea Pharmaceutical Co., Ltd.

MFDS item code 201901736 · Approved 2019.03.22 · Insurance code 696300550
First-line and recurrent maintenance treatment of ovarian cancer (e.g., fallopian tube cancer) responsive to platinum-based therapy
This medication is effectively used for ovarian cancer, tubal cancer, or primary peritoneal cancer. It is particularly applied as a monotherapy for maintenance in adult patients who have shown a partial or complete response to first-line platinum-based chemotherapy. Additionally, it is used as a monotherapy for maintenance in patients with platinum-sensitive recurrent high-grade serous ovarian cancer who have responded to second-line or subsequent platinum-based chemotherapy. This treatment helps to prevent cancer recurrence and maintain therapeutic efficacy. It plays an important role in stabilizing treatment outcomes for patients. Therefore, it is used as maintenance therapy for these cancer types associated with ovarian cancer.
The recommended starting dose of this drug is 200 mg (two 100 mg capsules) orally once daily. However, for patients weighing 77kg or more and with a platelet count of 150,000/µl or higher, the recommended starting dose is 300 mg (three 100 mg capsules) orally once daily. For maintenance treatment of first-line ovarian cancer, patients should start treatment with this drug within 12 weeks after their most recent platinum-based therapy. For maintenance treatment of recurrent ovarian cancer in the second or later line, patients should start treatment with this drug within 8 weeks after their most recent platinum-based therapy. Continue treatment with this drug until disease progression or unacceptable toxicity occurs. Administer this drug at approximately the same time each day. Do not chew, crush, or split the capsules before swallowing them whole. This drug may be taken with or without food. Taking it at bedtime may help manage nausea. If a dose is missed, skip it and take the next dose at the regularly scheduled time. If vomiting occurs or a dose is missed, do not take an additional dose. Starting dose: 200 mg/day (two 100 mg capsules); 300 mg/day (three 100 mg capsules) First dose reduction: 100 mg/day (one 100 mg capsule); 200 mg/day (two 100 mg capsules) Second dose reduction: Discontinue treatment; 100 mg/day* (one 100 mg capsule) *If a further dose reduction to less than 100 mg/day is required, discontinue treatment with this drug. For nonhematologic adverse reactions of CTCAE* Grade ≥ 3 that persist despite medical management: Withhold treatment with this drug for up to 28 days or until the adverse reaction resolves. Resume treatment with this drug at the reduced dose according to Table 1. If the patient experiences a treatment-related adverse reaction of CTCAE Grade ≥ 3 that persists for 28 days or longer while receiving 100 mg of this drug once daily, discontinue treatment. Monitor complete blood counts weekly during the first month of treatment, monthly for the subsequent 11 months, and periodically thereafter. Platelet count <100,000/μL First occurrence: Withhold treatment with this drug for up to 28 days and monitor blood counts weekly until the platelet count returns to ≥100,000/μL. Resume treatment with this drug at the same or a reduced dose according to Table 1. If the platelet count falls to <75,000/μL, resume treatment at a reduced dose. Second occurrence: Withhold treatment with this drug for up to 28 days and monitor blood counts weekly until the platelet count returns to ≥100,000/μL. Resume treatment with this drug at a reduced dose according to Table 1. If the platelet count does not return to an acceptable level within 28 days after treatment interruption, or if the patient has already had the dose reduced to 100 mg once daily, discontinue treatment with this drug.* Neutrophil count <1,000/μL or hemoglobin <8 g/dL: Withhold treatment with this drug for up to 28 days and monitor blood counts weekly until the neutrophil count returns to ≥1,500/μL or the hemoglobin level returns to ≥9 g/dL. Resume treatment with this drug at a reduced dose according to Table 1. If the neutrophil count and/or hemoglobin level does not return to an acceptable level within 28 days after treatment interruption, or if the patient has already had the dose reduced to 100 mg once daily, discontinue treatment with this drug.* Hematologic adverse reactions requiring transfusion: Consider platelet transfusion for patients with a platelet count of ≤10,000/μL. If other risk factors are present, such as concomitant use of anticoagulants or antiplatelet agents, consider discontinuing these medications and/or transfusing at a higher platelet count. Resume treatment with this drug at a reduced dose. *If myelodysplastic syndrome or acute myeloid leukemia (MDS/AML) is confirmed, permanently discontinue treatment with this drug. For patients with moderate hepatic impairment, administer this drug at a starting dose of 200mg once daily. Monitor for hepatotoxicity and reduce the dose further if necessary.
This medication may cause serious blood disorders such as myelodysplastic syndrome and acute myeloid leukemia; therefore, regular blood status checks should be performed during treatment. This medication may harm the fetus during pregnancy; thus, women who are pregnant or may become pregnant should avoid use and employ effective contraception during treatment and for 6 months afterward. Individuals with known allergies to any ingredient of this medication or specific inherited disorders like lactose intolerance should not take it. Patients hypersensitive to Yellow No. 4 (Tartrazine) should use this medication cautiously. Various side effects may commonly occur, including nausea, thrombocytopenia, anemia, fatigue, constipation, myalgia, vomiting, neutropenia, and others, hence symptoms should be closely monitored. Hematological toxicity may occur; routine blood tests should be done before and during treatment, and consultation with a specialist is required for any abnormal findings. Patients with hypertension or cardiovascular disease should frequently monitor their blood pressure and heart rate during treatment, seeking appropriate treatment if necessary. Reversible posterior leukoencephalopathy syndrome, a neurological side effect, may rarely occur; therefore, immediately inform medical personnel of symptoms like headache, seizures, or visual disturbances. While taking this medication, weakness, fatigue, or dizziness may occur; caution is needed when driving or operating machinery. Patients with renal or hepatic impairment may need dose adjustments, thus should take it according to their doctor's instructions. Pregnant or breastfeeding women should avoid using this medication, and it is recommended to discontinue breastfeeding for a certain period during and after treatment. In case of overdose, there is no specific antidote, so symptomatic treatment should be sought promptly, along with immediate consultation with medical staff. This medication should be kept out of reach of children, and expired medications should not be taken.
Myelodysplastic syndrome, acute myeloid leukemia, nausea, thrombocytopenia, anemia, fatigue, constipation, myalgia, abdominal pain, vomiting, neutropenia, appetite loss, leukopenia, insomnia, headache, dyspnea, rash, diarrhea, hypertension, cough, dizziness, acute kidney injury, urinary tract infection, magnesium deficiency, small bowel obstruction, intestinal perforation, pleural effusion, pancytopenia, hypersensitivity, reversible posterior leukoencephalopathy syndrome, confusion, stupor, hallucinations, cognitive impairment, non-infectious pneumonia, photosensitivity, hypertensive crisis, thrombocytopenic infection, neutropenic sepsis, febrile neutropenia, lymphopenia, renal failure, increased serum creatinine, increased blood urea, increased serum creatine, palpitations, mucositis, stomatitis, dyspepsia, xerostomia, low back pain, taste disturbances, anxiety, rhinitis, tachycardia, peripheral edema, hypokalemia, bronchitis, conjunctivitis, increased gamma-glutamyl transferase, weight loss, depression, epistaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be kept tightly closed in a container to prevent exposure to air or moisture. It is best to store at room temperature between 1 to 30 degrees Celsius. Proper storage will help preserve the medication's effectiveness for a longer period.
A hard capsule with a white to off-white powder in a purple upper and white lower part.
30 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowNiraparib Tosylate Monohydrate 159.4mg
Hard capsule · Prescription medication
Takeda Korea Pharmaceutical Co., Ltd.

Niraparib Tosylate Monohydrate 159.3mg
Tablet · Prescription medication
Takeda Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.